Predictors of long-term clinical response in patients with non-radiographic axial spondyloarthritis receiving certolizumab pegol.

ABSTRACT:

Background

Identification of predictive clinical factors of long-term treatment response may contribute to improved management of non-radiographic axSpA (nr-axSpA) patients. This analysis aims to identify whether any baseline characteristics or Week 12 clinical outcomes in nr-axSpA patients with elevated C-reactive protein (CRP) and/or sacroiliitis on magnetic resonance imaging (MRI) enrolled in the C-axSpAnd study are predictive of achieving clinical response after 1 year of certolizumab pegol (CZP).

Methods

C-axSpAnd (NCT02552212) was a phase 3, multicentre study, including a 52-Week double-blind, placebo-controlled period. Enrolled patients were randomised to CZP 200 mg Q2W or placebo. Predictors of Week 12 (CZP group only) and Week 52 clinical response were identified us

SUBMITTER: Maksymowych WP 

PROVIDER: S-EPMC8556993 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature